403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

June 27, 2007 at 7:03 PM

Dendreon stock gets big jolt from partnership rumors

Dendreon shares jumped 10 percent Tuesday in the wake of an analyst note that portrayed the Seattle biotech company as ripe for a lucrative partnership with Big Pharma.

Needham & Co.’s annual partnership report says that the number of partnerships in the biotech industry is poised to grow, according to Marketwatch. The report’s authors estimate Dendreon is likely to seek a partner from outside the U.S. to help with the marketing and development of Provenge, its prostate cancer-fighting drug.

The report “triggered the rumor mill,” says David Miller, an analyst at Seattle-based Biotech Stock Research. On Tuesday, Dendreon shares closed at $7.17, up 66 cents, or 10.14 percent.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx